About curis - CRIS
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
CRIS At a Glance
Curis, Inc.
Building C
Lexington, Massachusetts 02421
| Phone | 1-617-503-6500 | Revenue | 9.44M | |
| Industry | Biotechnology | Net Income | -7,582,000.00 | |
| Sector | Health Technology | Employees | 24 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CRIS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.376 |
| Price to Book Ratio | 2.337 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.292 |
| Enterprise Value to Sales | 1.011 |
| Total Debt to Enterprise Value | 0.169 |
CRIS Efficiency
| Revenue/Employee | 393,458.333 |
| Income Per Employee | -315,916.667 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.302 |
CRIS Liquidity
| Current Ratio | 0.491 |
| Quick Ratio | 0.491 |
| Cash Ratio | 0.36 |
CRIS Profitability
| Gross Margin | 97.734 |
| Operating Margin | -348.427 |
| Pretax Margin | -80.292 |
| Net Margin | -80.292 |
| Return on Assets | -24.222 |
| Return on Equity | N/A |
| Return on Total Capital | -107.09 |
| Return on Invested Capital | -53.911 |
CRIS Capital Structure
| Total Debt to Total Equity | 29.623 |
| Total Debt to Total Capital | 22.853 |
| Total Debt to Total Assets | 7.902 |
| Long-Term Debt to Equity | 7.836 |
| Long-Term Debt to Total Capital | 6.045 |